Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 37 | ECE2015 | Next issue

17th European Congress of Endocrinology

Guided Posters

Thyroid – hyperthyroidism and treatment

ea0037gp.27.01 | Thyroid – hyperthyroidism and treatment | ECE2015

The effect of TSH suppression therapy on the cortical bone geometry in the patients with differentiated thyroid cancer

Moon Jae Hoon , Choi Hoon Sung , Jung Chan Hyun , Kim Kyung Young , Park Young Joo , Park Do Joon , Kim Kyong Yeun

Background: TSH suppression therapy has been associated with hip and vertebral fracture. However, the relationship between TSH suppression and bone mineral density (BMD) remains controversial. The aim of this study was to evaluate the effect of TSH suppression therapy on cortical bone geometry in differentiated thyroid cancer (DTC) patients.Methods: This study included 122 subjects (19 men, 27 premenopausal women, and 75 postmenopausal women) who have be...

ea0037gp.27.02 | Thyroid – hyperthyroidism and treatment | ECE2015

MIVAT vs traditional thyroidectomy: a 5-year follow up in 284 cases

Bertocchi Elisa , Del Rio Paolo , Viani Lorenzo , Bonati Elena , Sianesi Mario

Introduction: Minimally invasive video-assisted thyroidectomy (MIVAT) was introduced for the treatment of selected patients. Our experience from 2005 indicates that outcome of surgery in differentiated thyroid cancer (DTC) is comparable in patients treated with MIVAT vs conventional thyroidectomy; minimally invasive technique is characterized by a better postoperative discomfort.Material and methods: In this prospective study from July 2005 to December 2...

ea0037gp.27.03 | Thyroid – hyperthyroidism and treatment | ECE2015

Clinical and biochemical factors affecting prognosis of disease persistence in micro papillary thyroid carcinomas

Saltiki Katerina , Apostolakis Michael , Kouki Sophia , Spanou Loukia , Athanasiadou Anastasia , Zapanti Evangelia , Alevizaki Maria

Introduction: In recent years, micro papillary thyroid carcinomas (mPTCs; ≤1.0 cm) are increasingly diagnosed. Although clinical course is usually favourable, disease persistence may occur and multiple treatments needed. We examined factors that could be predictors of clinical behaviour and disease persistence.Patients and methods: 478 mPTC patients (78.9% females) followed-up for 0.6–10 years were classified according to tumour size in group ...

ea0037gp.27.04 | Thyroid – hyperthyroidism and treatment | ECE2015

TIM16 inhibition enhances sensitivity to paclitaxel and decreases calcitonin secretion by reducing mitochondrial membrane potential in a human medullary thyroid carcinoma cell line

Gagliano Teresa , Riva Eleonora , Tagliati Federico , Matteotti Daniele , Brugnoli Valentina , Sambugaro Silvia , Bondanelli Marta , Gentilin Erica , Falletta Simona , Benfini Katiuscia , Di Pasquale Carmelina , Guerrini Remo , Salvadori Severo , degli Uberti Ettore , Zatelli Maria Chiara

TIM16, a protein of the translocase complex TIM23 of the mitochondrial inner membrane, is encoded by the Magmas a gene. Magmas silencing has been associated with a greater sensitivity to apoptotic stimuli in pituitary adenoma cell lines. We recently demonstrated that in a human medullary thyroid carcinoma cell line (TT) compound 5, a TIM16 inhibitor, was not cytotoxic but enhanced the proapoptotic effects of staurosporine. The aim of our study is to verify whether mithocondria...

ea0037gp.27.05 | Thyroid – hyperthyroidism and treatment | ECE2015

Effect of a very low dose of rituximab on active moderate–severe Graves' orbitopathy: an interim report

Vannucchi Guia , Campi Irene , Covelli Danila , Curro Nicola , Dazzi Davide , Avignone Sabrina , Sina Clara , Guastella Claudio , Pignataro Lorenzo , Salvi Mario

Previous studies have shown that Rituximab (RTX) is effective as a disease modifying drug at doses of 500 mg or 1000×2 mg in active Graves’ orbitopathy (GO). We have conducted a pilot study (EUDRACT 2012-001980-53) in which patients with active moderate-severe GO were treated with a single infusion of low dose RTX (100 mg). Ten patients were enrolled of whom seven completed the study at 52 weeks. Five patients did not respond to a previous treatment with i.v. methylp...

ea0037gp.27.06 | Thyroid – hyperthyroidism and treatment | ECE2015

hCG levels are essential for the correct interpretation of gestational TSH levels: the clinical risk assessment of premature delivery

Korevaar Tim , Medici Marco , Chaker Layal , Tiemeier Henning , Visser Theo , Peeters Robin

Context: High maternal TSH and/or low FT4 during pregnancy is associated with an increased risk of premature delivery. hCG is the main determinant of thyroid function changes during pregnancy but has a versatile pattern with high inter and intra-individual variability. We hypothesised that the correct interpretation of thyroid function tests and its use in the risk assessment of premature delivery during pregnancy depend on hCG levels.Design, ...

ea0037gp.27.07 | Thyroid – hyperthyroidism and treatment | ECE2015

Plasmapheresis in thyroid storm caused by exogenous thyroid hormone intake: a case series

da Silva Tiago Nunes , Pereira Bernardo Dias , Luiz Henrique Vara , Macau Ricardo , Matos Ana Catarina , Manita Isabel , Bravo Pedro , Cordeiro Maria Carlos , Raimundo Luisa , Portugal Jorge

Thyroid storm (TS) is one extreme of a continuum beginning with thyrotoxicosis. It’s rarely caused by exogenous thyroid hormone intake (ETHI). Aggressive medical therapy is the cornerstone of treatment; nevertheless, it might not be sufficient. Plasmapheresis is an extracorporeal technique that can rapidly lower thyroid hormone levels. The aim of this study was to assess the efficacy of plasmapheresis in TS secondary to ETHI. We evaluated retrospectively all TS cases (Bur...

ea0037gp.27.08 | Thyroid – hyperthyroidism and treatment | ECE2015

There is a detectable immune activity in the orbits of all patients diagnosed with Graves' disease regardless of later development of Graves' orbitopathy

Berta Eszter , Ujhelyi Bernadett , Szabados Lajos , Galuska Laszlo , Erdei Annamaria , Gazdag Annamaria , Halmi Sandor , Nagy Endre , Bodor Miklos

Graves’ orbitopathy (GO) is a common complication of Graves’ disease (GD) which is often responding poorly to therapy. GO may develop before or together with, or during the course of GD. In an individual patient, the development of GO cannot be predicted. We assumed that orbital autoimmune activity is predictable using orbital 99mTc-labelled diethylenetriamine pentaacetic acid (99mTc-DTPA) SPECT. We aimed to determine whether any orbital autoimmune activity can be id...